OVERVIED

Hexarelin (5 mg x 10) is a synthetic growth hormone–releasing peptide (GHRP) recognized for its strong stimulation of growth hormone (GH) secretion. It binds to ghrelin (GHS-R1a) receptors in the pituitary and hypothalamus, triggering a pronounced increase in GH release. Due to its potency, Hexarelin has been explored in research settings for its potential effects on muscle development, recovery support, fat metabolism, and overall anabolic signaling. Some experimental studies have also examined its possible cardioprotective properties. Because of its intensity compared to other GHRPs, careful dosing considerations are often emphasized in research discussions to help manage potential elevations in prolactin or cortisol levels. The 5 mg x 10 format typically indicates multiple vials intended for structured research protocols.

CJC-1295 no DAC (5 mg x 10) is a modified growth hormone–releasing hormone (GHRH) analog designed to stimulate the body’s natural pulsatile GH release. The “no DAC” version has a shorter half-life, allowing for more controlled and time-specific administration compared to the longer-acting DAC variant. It is frequently referenced in performance and longevity research for its potential role in supporting lean body composition, sleep quality, and recovery. When discussed together, Hexarelin and CJC-1295 no DAC are often described as complementary compounds that activate different receptors to enhance endogenous growth hormone output through synergistic mechanisms.